13F reference period
n/a
Security Snapshot
Virax Biolabs Group Ltd - Ordinary shares, par value $0.001 per share (VRAX) Institutional Ownership
CUSIP: G9495L125
13F Institutional Holders and Ownership History from Q4 2023 to Q2 2026
Institutions Reporting
Shares (Excl. Options)
n/a
Price
$0.15
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary shares, par value $0.001 per share
- Symbol
- VRAX on Nasdaq
- Shares outstanding
- 20,044,870
- SEC-reported price per share
- $0.15
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- VRAX - Virax Biolabs Group Ltd - Ordinary shares, par value $0.001 per share is tracked under CUSIP G9495L125.
- 13F reference-period holder data is not available.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder data for the Q3 2026 reference period is not available.
- Available periods remain in the history table; they do not substitute for the headline period.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
G9495L125
13F reference period
n/a
13F holders
13D/G owners
2
CIK / CUSIP context first
VRAX full holder history
Virax Biolabs Group Ltd SEC filings
Virax Biolabs Group Ltd company facts
Virax Biolabs Group Ltd insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G9495L125:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
VRAX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5% | -50% | $170,041 | +$29,976 | 1,000,239 | +21% | Armistice Capital, LLC | 31 Mar 2026 |
| Foster James Alexander Cunliffe | 8.3% | +14% | $232,199 | +$30,634 | 368,570 | +15% | James Foster | 31 Mar 2025 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Headline period
n/a
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 0 | $0 | -$202,209 | $0.15 | 0 |
| 2026 Q1 | 919,547 | $202,209 | +$190,127 | $0.22 | 3 |
| 2025 Q4 | 34,959 | $12,085 | -$41,527 | $0.35 | 5 |
| 2025 Q3 | 94,809 | $57,043 | +$29,376 | $0.60 | 4 |
| 2025 Q2 | 35,155 | $28,617 | -$38,558 | $0.80 | 2 |
| 2025 Q1 | 63,098 | $71,534 | -$27,747 | $1.14 | 4 |
| 2024 Q4 | 63,007 | $141,366 | -$294,712 | $2.25 | 7 |
| 2024 Q3 | 218,370 | $423,638 | +$328,879 | $1.94 | 5 |
| 2024 Q2 | 70,777 | $81,774 | +$68,070 | $1.16 | 7 |
| 2024 Q1 | 17,460 | $12,519 | -$182,221 | $0.72 | 3 |
| 2023 Q4 | 133,508 | $195,382 | +$195,382 | $1.46 | 4 |